Earlier this month, the company TauRX Pharmaceuticals Ltd. announced the submission of a marketing authorisation application (MAA) for its drug hydromethylthionine mesylate (HMTM) to the UK Medicines and Healthcare products Regulatory Agency (MHRA). HMTM is an oral treatment for mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease. The MAA for HMTM is being reviewed under the Innovative Licencing and Access Pathway, an accelerated regulatory pathway for novel medicines aiming to treat life-threatening or seriously debilitating conditions for which there is a significant patient or public health need. In their press release, the company explained that the MAA is based on evidence from three Phase 3 clinical trials of HMTM, including recently-released data from the LUCIDITY trial. Read the full press release: